Clincosm LogoSign in Get a demo

A Phase 1 Clinical Study to Investigate the Pharmacokinetics and Safety/Tolerability of SA001 in Healthy Male Volunteers

Sponsor
Samjin Pharmaceutical Co., Ltd. (Industry)
Overall Status
Completed
CT.gov ID
NCT02470286
Collaborator
(none)
40
Enrollment
1
Location
5
Arms
3.1
Actual Duration (Months)
13.1
Patients Per Site Per Month

Study Details

Study Description

Brief Summary

The purpose of this phase1 study is to investigate the pharmacokinetics, safety and tolerability of a single oral dose of SA001 and its active metabolite in healthy male volunteers.

Condition or Disease Intervention/Treatment Phase
  • Drug: SA001 60mg or Placebo
  • Drug: SA001 120mg or Placebo
  • Drug: SA001 180mg or Placebo
  • Drug: SA001 240mg or Placebo
  • Drug: SA001 300mg or Placebo
 Phase 1

Detailed Description

This study consists of Part 1 followed Part 2.

Part 1 (Dose escalation study, SA001 60mg~300mg dose group) The part 1 is a dose escalation study. The starting dose is SA001 60mg, and the maximum dose is 300mg. Each dose group is assigned to SA001 or Placebo in a ratio of 3:1. The pharmacokinetics, safety and tolerability of SA001 and its metabolite are investigated after a single oral administration on the fasting state.

Part 2 (Single dose and food effect study, SA001 120mg and 300mg dose group) The purpose of this part 2 is to evaluate the food effect of a high-fat diets(HFDs) on the single oral dose pharmacokinetics of SA001 and its metabolite.

Study Design

Study Type:
Interventional
Actual Enrollment :
40 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose:
Other
Official Title:
A Phase1, Double-blind, Randomized, Placebo-control, Single Center, Single Dose Administration, Dose Escalation Study to Investigate the Pharmacokinetics, Safety and Tolerability of SA001 in Healthy Male Volunteers.
Actual Study Start Date :
Jun 29, 2015
Actual Primary Completion Date :
Sep 18, 2015
Actual Study Completion Date :
Sep 30, 2015

Arms and Interventions

Arm Intervention/Treatment
Experimental: Cohort 1 (SA001 60mg or Placebo)

6 subjects receiving a single dose of 60mg SA001 and 2 subjects receiving placebo

Drug: SA001 60mg or Placebo
Study Drug: SA001 60mg Comparator: Placebo Cohort 1 in the part 1 (Dose escalation study)
Experimental: Cohort 2 (SA001 120mg or Placebo)

6 subjects receiving a single dose of 120mg SA001 and 2 subjects receiving placebo

Drug: SA001 120mg or Placebo
Study Drug: SA001 120mg Comparator: Placebo Cohort 2 in the part 1 (Dose escalation study) and part 2 (Food effect study)
Experimental: Cohort 3 (SA001 180mg or Placebo)

6 subjects receiving a single dose of 180mg SA001 and 2 subjects receiving placebo

Drug: SA001 180mg or Placebo
Study Drug: SA001 180mg Comparator: Placebo Cohort 3 in the part 1 (Dose escalation study)
Experimental: Cohort 4 (SA001 240mg or Placebo)

6 subjects receiving a single dose of 240mg SA001 and 2 subjects receiving placebo

Drug: SA001 240mg or Placebo
Study Drug: SA001 240mg Comparator: Placebo Cohort 4 in the part 1 (Dose escalation study)
Experimental: Cohort 5 (SA001 300mg or Placebo)

6 subjects receiving a single dose of 300mg SA001 and 2 subjects receiving placebo

Drug: SA001 300mg or Placebo
Study Drug: SA001 300mg Comparator: Placebo Cohort 5 in the part 1(Dose escalation study) and part 2 (Food effect study)

Outcome Measures

Primary Outcome Measures

  1. The incidence of treated related adverse event [Part1: Day-2(administration) to approximately Day 15 (Post study visit)]

    Safety/Tolerability Assessment in the part 1

Secondary Outcome Measures

  1. Area under the curve (AUC) from time 0 to the time of the last quantifiable concentration (AUC0-tlast) of SA001 and its metabolite [Part1: predose and 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 8, 12, 24, 32, and 48 hours postdose, Part2: predose and 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 8, 12, 24, 32, and 48 hours postdose]

  2. Area under the curve (AUC) from time 0 extrapolated to infinity (AUC0-∞) of SA001 and its metabolite [Part1: predose and 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 8, 12, 24, 32, and 48 hours postdose, Part2: predose and 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 8, 12, 24, 32, and 48 hours postdose]

  3. Maximum observed plasma concentration (Cmax) of SA001 and its metabolite [Part1: predose and 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 8, 12, 24, 32, and 48 hours postdose, Part2: predose and 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 8, 12, 24, 32, and 48 hours postdose]

  4. Time to reach the maximum observed plasma concentration (tmax) of SA001 and its metabolite [Part1: predose and 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 8, 12, 24, 32, and 48 hours postdose, Part2: predose and 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 8, 12, 24, 32, and 48 hours postdose]

  5. t1/2 of SA001 and its metabolite [Part1: predose and 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 8, 12, 24, 32, and 48 hours postdose, Part2: predose and 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 8, 12, 24, 32, and 48 hours postdose]

  6. CL/F of SA001 and its metabolite [Part1: predose and 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 8, 12, 24, 32, and 48 hours postdose, Part2: predose and 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 8, 12, 24, 32, and 48 hours postdose]

  7. Vz/F of SA001 and its metabolite [Part1: predose and 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 8, 12, 24, 32, and 48 hours postdose, Part2: predose and 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 8, 12, 24, 32, and 48 hours postdose]

  8. CLR of SA001 and its metabolite [Part1: predose and 0 ~ 4, 4 ~ 8, 8 ~ 12, 12 ~ 24, 24 ~ 32 and 32 ~ 48 hours postdose, Part2: predose and 0 ~ 4, 4 ~ 8, 8 ~ 12, 12 ~ 24, 24 ~ 32 and 32 ~ 48 hours postdose]

    CLR = Ae / AUCinf (Ae: total amount excreted in the urine)

  9. Fraction recovered unchanged in urine (FR) of SA001 and its metabolite [Part1: predose and 0 ~ 4, 4 ~ 8, 8 ~ 12, 12 ~ 24, 24 ~ 32 and 32 ~ 48 hours postdose, Part2: predose and 0 ~ 4, 4 ~ 8, 8 ~ 12, 12 ~ 24, 24 ~ 32 and 32 ~ 48 hours postdose]

Eligibility Criteria

Criteria

Ages Eligible for Study:
19 Years to 45 Years
Sexes Eligible for Study:
Male
Accepts Healthy Volunteers:
Yes
Inclusion Criteria:

  1. 19 years to 45 years (Healthy male Korean)

  2. Body weight of 55 to 90kg; and BMI of 18.0 to 27.0 kg/m^2

  3. Subject who voluntarily agrees to participate in this study and has given a written informed consent, after fully understanding the detailed explanation of this study

Exclusion Criteria:
  1. Subject with a disease history of any clinically significant condition as below.
  • Liver, Kidney, nervous system, immune system, respiratory system, endocrine system, tumor, cardiovascular disease or mental illness (mood disorder or obsessive-compulsive disorder etc.) etc.

  1. Subject with a history of gastrointestinal disease (Crohn's disease, ulcer, acute or chronic pancreatitis, etc.) or gastrointestinal surgery (except simple appendicectomy or hernia surgery) that may affect the absorption of the study drug

  2. Subject with a history of clinically significant hypersensitivity or hypersensitivity reactions to drugs (aspirin, antibiotics, etc.)

  3. Serum ALT(SGPT)/AST(SGOT) >1.5×institutional upper limit normal (ULN)

  4. eGFR< 90mL/min/1.73m^2

  5. Systolic blood pressure <100 mmHg or >160 mmHg

  6. Diastolic blood pressure <60 mmHg or >100 mmHg

  7. Inadequate cardiac function confirmed by 12-lead ECG findings at screening as followings:

  • QTcF > 430msec (males)

  • PR interval > 200msec or < 110msec

  • QRS complex > 120msec

  • Evidence of 2nd- or 3rd-degree atrioventricular (AV) block

  • Pathologic Q waves (defined as Q-wave > 40msec or depth > 0.5mV)

  • Evidence of ventricular preexicitation, left bundle branch block (LBBB), right bundle branch block (RBBB, Incomplete RBBB)

  1. Subject with risk factors for Torsade de pointes such as long QT syndrome, family history of sudden death, heart failure, hypokalemia, and arrhythmias

  2. Subject with a history of drug abuse within 60 days prior to screening or who is positive for drugs of abuse in urine tests at screening

  3. Subject who received any prescription drug or herbal medicine within 14 days prior to the first administration of the Investigational product

  4. Subject who received any drugs such as

  • Prescription drug or herbal medicine within 14 days prior to the first administration of the investigational products

  • Over the counter (OTC) or vitamin within 7 days prior to the first administration of the investigational products

  1. Subject who received other investigational products within 90 days prior to the first administration of the investigational products

  2. Subject who continuously drink alcohol (more than 21 units/week, 1 unit = 10 g of pure alcohol) or cannot abstain from alcohol during the study period

  3. Subject with history of smoking within 90 days prior to the first administration of the investigational products

  4. Subject who cannot prohibit grapefruit/ caffeine-containing foods during the study period from 3 days before the first administration of the investigational products

  5. Man of reproductive potential not willing to use contraceptive measures during the study period

  6. Subject not eligible for study participation in the opinion of the investigator

Contacts and Locations

Locations

Site City State Country Postal Code
1 Seoul National University Hospital Seoul Korea, Republic of

Sponsors and Collaborators

  • Samjin Pharmaceutical Co., Ltd.

Investigators

  • Principal Investigator: Kyung-sang Yu, M.D., Ph.D., M.B.A, Seoul National University College of Medicine / Seoul National University Hospital

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Samjin Pharmaceutical Co., Ltd.
ClinicalTrials.gov Identifier:
NCT02470286
Other Study ID Numbers:
  • SJSA001
First Posted:
Jun 12, 2015
Last Update Posted:
Mar 24, 2022
Last Verified:
Mar 1, 2022

Study Results

No Results Posted as of Mar 24, 2022